Inhalation therapy Yupeli gets the latest positive data in clinical Phase 3 trials

COPD, a serious disease with an increasing incidence, is the third leading cause of death in the United States, with nearly 15.7 million confirmed cases, or 6.4 percent of the populationyesterday (September 18), Theravance Biopharma(with Mylan) announced its inhalation therapy, Yupeli, the latest positive data in the clinical phase 3trialtrial data show that the treatment for chronic obstructive pulmonary disease (COPD) can effectively help patients with moderate to severe COPD to reduce the risk of deterioration by 15%-18%At week 52, the patient group treated with Yupelri once a day showed better results than the placebo group and the tiotropium groupAbout YupelriYupelri is an innovative long-acting toxin-alkali antagonist (LAMA) inhalation therapy that targetsnew drugfor moderate to severe COPD (application is currently under going on for review of theFDA(review, expected target approval date (PDUFA) will be November 13, 2018If approved, Yupeli will be the first long-lasting atomized broncho dilator for COPD and will be compatible with any standard jet atomizer on the marketin addition to, Yupeli's application on quantitative atomized inhalers and dry powder inhalers is stable and good, proving that LAMA can not only be the backbone of COPD continuing therapy, but also become theof a new generation of handheld compositedrugs (a solid foundation for research and development) the results of the study
the results included two 12-week-long randomized double-blind, placebo-controlled parallel key 3 trials involving 1,229 patients with moderate to severe COPD trial data showed an average annual deterioration rate of 0.47 in the 175 mcg Yupelri patient group at 175 mcg per day, 0.45 in the 88 mcg Yupelri patient group at a daily time, and a decrease of 15% and 18% respectively compared to 0.55 in the placebo group in addition to this, the 12-month Phase 3 safety trial included 1,055 patients with moderate to severe COPD The results showed an average annual deterioration rate of 0.38 in the 175 mcg Yupelri patient group at one time, 0.57 in the 88 mcg Yupelri patient group at one time and 0.46 in the 18 mcg tiotropium patient group at 18 mcg at a time It was shown that a daily 175 mcg Yupelri comparison tiotropium reduced the COPD deterioration rate by 17%